Published in:
Open Access 01-12-2017 | Research article
Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
Published in: BMC Urology | Issue 1/2017
Login to get accessAbstract
Background
There has been a change in the focus of attention from prostate to bladder, as the etiology of lower urinary tract symptoms (LUTS) makes the bladder an additional therapeutic target. This study aims to evaluate the use of resources and costs associated with the addition of an antimuscarinic (AM) in patients receiving an alpha-adrenergic-blocker (AAB) for the treatment of LUTS linked to benign prostatic hyperplasia (BPH).
Methods
A multicentre, retrospective study was conducted using patient records from the databases of six primary care centers in Spain. Men with moderate-to-severe LUTS (IPSS > 7) who were initiated on AM treatment between January 2010 and December 2012 without previous treatment with an AM or 5-alpha reductase inhibitor (5-ARI) and had been on treatment with an AAB for a minimum of 6 months prior to the addition of the AM with a minimum of two records in the database were included. Comorbidity, treatment persistence, and use of resources and costs (direct and indirect) during monotherapy (AAB alone) and following the introduction of combination therapy (AAB + AM) over a treatment period of up to a year were compared. A paired sample Student t-test was performed where p < 0.05 were considered significant.
Results
One hundred and ninety-one patients (mean age (SD): 70 (10.4) years) were treated with combination therapy. Treatment persistence on combination therapy after 12 months was 65.4% (95% CI: 58.8-72.2%). Use of resources was numerically lower after initiation of combination therapy vs pre-treatment (AAB alone) period for medical visits (/year/patient) (13.4 (4.6) vs 15.4 (4.4) p < 0.010), percentage of patients using concomitant medication (13.3% vs 19.1%) and use of pads (9.7% vs 13.4%) among others analyzed. Comparing AAB vs AAB + AM, there were a numeric reduction in total cost/year (€2399 vs €2011; p = 0.135) and a reduction of costs due to medical visits (€645 vs. €546; p = 0.003) and concomitant medication (€181 vs. €101; p = 0.009).
Conclusions
The addition of an AM agent in patients treated for LUTS with AAB is associated with a lower use of healthcare resources in terms of number of medical visits, and concomitant medications required, thereby leading to reduction of overall costs to the healthcare system.